Loading…
Academic Journal
Association of Circulating Phenylacetylglutamine With Multi‐Vessel Coronary Disease Severity and Outcomes in ST‐Segment–Elevation Myocardial Infarction
Peng Zhao, Nana Dong, Yan Wang, Suhong Zhao, Yanan Tian, Zhifeng Qin, Xiaofang Ban, Feiyuan Han, Li Meng, Fan Yang, Yidan Wang, Yunfei Wu, Zhongzhi Yu, Qinglu Xu, Xinyue Li, Shuo Li, Huibin Liu, Shaohong Fang, Wanqing Xie, Bo Yu, Xinxin Liu, Jinwei Tian
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 14, Iss 4 (2025)
Saved in:
| Title | Association of Circulating Phenylacetylglutamine With Multi‐Vessel Coronary Disease Severity and Outcomes in ST‐Segment–Elevation Myocardial Infarction |
|---|---|
| Authors | Peng Zhao, Nana Dong, Yan Wang, Suhong Zhao, Yanan Tian, Zhifeng Qin, Xiaofang Ban, Feiyuan Han, Li Meng, Fan Yang, Yidan Wang, Yunfei Wu, Zhongzhi Yu, Qinglu Xu, Xinyue Li, Shuo Li, Huibin Liu, Shaohong Fang, Wanqing Xie, Bo Yu, Xinxin Liu, Jinwei Tian |
| Publication Year |
2025
|
| Source |
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 14, Iss 4 (2025)
|
| Description |
Background There is a lack of evidence regarding the association between plasma phenylacetylglutamine levels and lesion severity and clinical prognosis in patients with ST‐segment elevation myocardial infarction (STEMI) with multivessel coronary disease (MVCD). This study aims to investigate the potential of phenylacetylglutamine as a biomarker for major adverse cardiovascular events (MACEs) of patients with STEMI and MVCD. Methods and Results Clinical data and blood samples were collected from 631 patients with STEMI and MVCD, who underwent primary percutaneous coronary intervention. Quantitative coronary angiography analysis was performed using the QAngio XA 7.3 system. Plasma phenylacetylglutamine concentrations were measured by rapid resolution liquid chromatography quadrupole time‐of‐flight mass spectrometry. Among a total of 631 patients, median plasma phenylacetylglutamine level was 3.8 (2.1–6.8) μmol/L and the cumulative MACE rate at follow‐up was 12%. Plasma phenylacetylglutamine levels of patients with MACE were significantly higher than patients without MACE. We employed restricted cubic spline, Kaplan–Meier curves, and Cox proportional hazard models to explore the association between plasma phenylacetylglutamine and prognosis of patients with STEMI and MVCD. Per SD, an increment in phenylacetylglutamine was associated with a 24% higher risk of complexity lesion. Higher phenylacetylglutamine level was an independent predictor of MACEs (hazard ratio [HR], 2.76 [95% CI, 1.62–4.72]). A novel prognostic scoring system was established by combining phenylacetylglutamine levels with the synergy between percutaneous coronary intervention with Taxus and cardiac surgery score, with higher scores significantly increasing the risk of MACEs (HR, 4.01 [95% CI, 2.04–7.89]). Conclusions Phenylacetylglutamine levels were associated with lesion complexity and prognosis, may serve as a novel biomarker in patients with STEMI and MVCD.
|
| Document Type |
article
|
| Language |
English
|
| Publisher Information |
Wiley, 2025.
|
| Subject Terms | |
